to Explore Neuralstem Cells' Potential in Lou Gehrig's Disease Treatment
ROCKVILLE, Md., Aug. 30 /PRNewswire-FirstCall/ -- Stem cell company,
Neuralstem, Inc. (Amex: CUR), today announced it has entered into a
collaborative agreement with the ALS Clinic at University of Michigan Health
System, directed by Dr. Eva Feldman, M.D., Ph.D., the De Jong Professor of
Neurology at the U-M Medical School. The goal of the collaboration is to
provide further proof-of-principle data to move Neuralstem's spinal cord stem
cells into patients with Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's
disease. ALS is a motor neuron disease, which strikes people between the ages
of 40 and 70. As many as 30,000 Americans have the disease at any given time.
"We are honored and excited to be working with Dr. Feldman and the
University of Michigan ALS Clinic," said Neuralstem CEO, Richard Garr. "It is
not only a world class research organization, but also clearly dedicated to,
and deeply involved in, the care and treatment of the ALS patients themselves.
Dr. Feldman and her team will be a tremendous partner in helping us to achieve
our goal, which is to be able to treat ALS patients with our Neuralstem
"We are excited about working with Neuralstem's technology and exploring
the ways in which it might lead to treatment for ALS patients," said Dr.
Feldman, who is also the Director at the U-M Program for Neurology Research
and Discovery, "At the Michigan ALS clinic, we are working as hard and as fast
as we can to try to find treatments for this terrible disease."
Neuralstem's patent-protected technology enables, for the first time, the
ability to produce neural stem cells of the human brain and spinal cord in
commercial quantities, and the ability to control the differentiation of these
cells into mature, physiologically relevant human neurons and glia. The
Company expects that its first Investigational New Drug (IND) application will
be for the treatment of Ischemic Paraplegia, a form of paraplegia that
sometimes results from the surgery to repair aortic aneurysms and for which
there is no effective treatment. The Company hopes to submit its initial IND
application to the FDA and begin its first human trial during calendar year
Major Central Nervous System diseases targeted by the Company with
research programs currently underway include: Ischemic Paraplegia, Traumatic
Spinal Cord Injury, ALS, and Parkinson's disease. The company's cells recently
extended the life of rats with ALS (Lou Gehrig's disease) in a paper published
in the journal TRANSPLANTATION, and were deemed viable for continued work in
neurodegenerative spinal conditions. Neuralstem cells also recently reversed
paralysis in rats with Ischemic Spastic Paraplegia, a form of paralysis that
can result from the surgery to repair aortic aneurysms, as reported in
NEUROSCIENCE (http://www.neuroscience-ibro.com/ ). The company has also
developed immortalized human neural stem cells for in-vitro use in drug
development for the academic and pharmaceutical markets. For further
information, please visit http://www.neuralstem.com .
Cautionary Statement Regarding Forward Looking Information
This presentation may contain forward-looking information about
Neuralstem, Inc. which are intended to be covered by the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. Forward- looking statements are statements that are not
historical facts. These statements can be identified by the use of forward-
looking terminology such as "believe," "expect," "may," "will," "should,"
"project," "plan," "seek," "intend," or "anticipate" or the negative thereof
or comparable terminology, and include discussions of strategy, and statements
about industry trends and Neuralstem's future performance, operations and
products. This and other "Risk Factors" contained in Neuralstem's public
filings with the SEC should be read in connection with this release. For
further information on Neuralstem, please review the company's filings with
the SEC including its Annual Report filed on Form 10-KSB for the period ended
December 31, 2006, as well as the company's subsequent filings.
SOURCE Neuralstem, Inc.
/CONTACT: Richard Garr, President Neuralstem, Inc.,
+1-301-366-4960; Media, Deanne Eagle of Planet Communications,
+1-917-837-5866; Investor Relations, Ira Weingarten, +1-805-897-1880, or Steve
Chizzik, +1-908-688-9111, both of Equity Communications/
/Web site: http://www.neuralstem.com
CO: Neuralstem, Inc.
ST: Maryland, Michigan
IN: HEA MTC BIO EDU HED
-- NETH004a --
4335 08/30/2007 08:00 EDT http://www.prnewswire.com